NCT02661932CompletedPhase 4
Fertility Preservation in Breast Cancer Patients
Efficiency and Safety Study of Ovarian Stimulation With Letrozole for Fertility Preservation in Breast Cancer Patients
Source: ClinicalTrials.gov · Last updated 31 Jan 2025
Brief summary (registry, in English)
The purpose of this study is to evaluate efficiency and safety of controlled ovarian stimulation (COS) associated with an aromatase inhibitor (letrozole) for fertility preservation in breast cancer patients.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 65 (actual)
- First submitted
- 23 Dec 2015
- Start date
- Nov 2012
- Primary completion date
- Mar 2018
- Lead sponsor
- Erasme University Hospital
- Diseases
- Ovarian cancer
- NCT number
- NCT02661932
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 65
- From Nov 2012 to the primary completion date, Mar 2018
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Surgical contra-indications
Other illness
- Metastatic breast cancer
- Known premature ovarian failure
Other
- Basal FSH \> 20 IU(International Unit)
Who the study is looking for
- Breast cancer female patients of less than 41 years old
- Addressed to fertility preservation Unit before starting chemotherapy
Age in the registry: 18 years to 40 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Erasme-CUB Coordinator of this site? Confirm its status | Brussels | Belgium | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.